Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fedratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 10/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 4/20 | 1.00 |
| ▸ | BRD4 | O60885 | 13/20 | 1.00 |
| ▸ | JAK1 | P23458 | 10/20 | 1.00 |
| ▸ | JAK3 | P52333 | 7/20 | 1.00 |
| ▸ | TYK2 | P29597 | 4/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | WEE1 | P30291 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fedratinib SCHEMBL29351417 | 1.00 | BRD4 (1.00) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL2734027 | 0.99 | BRD4 (0.98) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL29362183 | 0.98 | BRD4 (0.97) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL2732092 | 0.98 | BRD4 (0.97) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL21773088 | 0.95 | BRD4 (0.91) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL21773035 | 0.95 | BRD4 (0.91) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL21784856 | 0.93 | BRD4 (0.87) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL29188523 | 0.93 | BRD4 (0.87) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL31077598 | 0.93 | BRD4 (0.87) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL31163072 | 0.93 | JAK1 (0.86) | BRD4JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165145-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | UNIV CALIFORNIA (US) | 2024-05-23 | — | — | US | claimed |
| EP-4159216-A1 | COMPOSITIONS FOR TREATING MYELOFIBROSIS | Impact Biomedicines, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| EP-2635282-B1 | COMPOSITIONS FOR TREATING MYELOFIBROSIS | IMPACT BIOMEDICINES INC (US) | 2022-09-28 | — | — | EP | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | claimed |
| US-20210244735-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | IMPACT BIOMEDICINES, INC. | 2021-08-12 | — | — | US | claimed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | claimed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | claimed |
| US-10391094-B2 | Compositions and methods for treating myelofibrosis | IMPACT BIOMEDICINES, INC. (US) | 2019-08-27 | — | — | US | claimed |
| US-20190247413-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-08-15 | — | — | US | claimed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | claimed |
| US-20140377221-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-12-25 | — | — | US | claimed |
| EP-2806883-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | Dnatrix Inc. (US) | 2014-12-03 | — | — | EP | claimed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | claimed |
| US-20130252988-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | TARGEGEN, INC. (US) | 2013-09-26 | — | — | US | claimed |
| US-20130243853-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | claimed |
| WO-2013112942-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNA TRIX, INC. (US) | 2013-08-01 | — | — | WO | claimed |
| WO-2013059548-A9 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING JAK2 INHIBITOR | SANOFI (FR) | 2013-06-06 | — | — | WO | claimed |
| WO-2013059548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING JAK2 INHIBITOR | SANOFI (FR) | 2013-04-25 | — | — | WO | claimed |
| WO-2013013195-A1 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA | SANOFI (FR) | 2013-01-24 | — | — | WO | claimed |
| WO-2012060847-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | TARGEGEN, INC. (US) | 2012-05-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | JAK2 3633/4885FLT3 2326/4885BRD4 699/4885 |
| US-20130243853-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | JAK2, NPM1, MCL1 | JAK2 1/4885FLT3 46/4885BRD4 39/4885 |
| US-10391094-B2 | Compositions and methods for treating myelofibrosis | JAK2, NPM1, MCL1 | JAK2 1/4885FLT3 46/4885BRD4 39/4885 |
| US-20130252988-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | JAK2, NPM1, MCL1 | JAK2 1/4885FLT3 46/4885BRD4 39/4885 |
| US-20210244735-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | JAK2, NPM1, MCL1 | JAK2 1/4885FLT3 46/4885BRD4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.